Skip to main content
OpenTrials
Completed

NCT Number: NCT05280925

Episodic Future Thinking to Improve Management of Type 2 Diabetes: Remote Delivery and Outcomes Assessment

Successful management of type 2 diabetes (T2D) requires adherence to a dietary, physical activity, and medication plan agreed upon between a patient and their healthcare providers. The lifestyle changes involved in these collaborative care plans (CCPs) often provide little to no short-term benefit and may instead be aversive (e.g., caloric restriction and physical activity). However, these changes provide critical health benefits in the future, allowing patients with T2D to halt or reverse disease progression and avoid T2D-related complications (e.g., renal disease or diabetic retinopathy). Thus, successful management of T2D requires one's present behavior to be guided by future outcomes. Unfortunately, accumulating evidence indicates that individuals with T2D and prediabetes show elevated rates of delay discounting (i.e., devaluation of delayed consequences). Moreover, high rates of delay discounting are cross-sectionally and longitudinally associated with poor treatment adherence and clinical outcomes in T2D and prediabetes. These data suggest that high rates of delay discounting prevent successful management of T2D through a mechanism in which the health benefits of lifestyle changes are too delayed to motivate behavioral change. Thus, we believe delay discounting serves as a therapeutic target in T2D, where improving participants' valuation of the future will facilitate healthy lifestyle changes and, in turn, improve T2D management. This study will conduct a randomized 24-week remote clinical trial comparing repeated measures ANOVA, with group (episodic future thinking [EFT]/control) and area (urban vs. rural) as between-subjects factors, and time (baseline, week 8, and week 24 assessments) as within-subjects factors in adults with type 2 diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fralin Biomedical Research Institute at VTC

Roanoke, Virginia, 24016, United States

About this study

In a 24-week trial, 120 participants from both urban (n = 60) and rural (n = 60) areas will be assigned receive either remotely delivered episodic future thinking or a control condition. Participants will be prompted three times daily to engage in episodic future thinking or control thinking. All participants will also receive virtual diet and physical activity support; self-monitoring of diet, activity, and weight; and case management. Outcome measures will be assessed at baseline, 8 weeks, and 24 weeks.

In the week following informed consent, participants will complete remote assessments of dietary intake (ASA-24 food recalls) and self-reported physical activity (IPAQ-SF), as well as self-administered survey (requiring approximately 10 minutes) to obtain sociodemographic information and delay discounting measures.

The week following baseline, all participants will begin phone-based case management; online self-monitoring of diet, activity, and weight; and diet and activity support. Beginning in Week 3, participants will begin episodic future thinking or control thinking conditions. Here, participants assigned to the EFT group will complete an episodic event generation task to generate a number of positive, vivid events that may occur at several time frames in the future (1 month, 3 months, 6 months, 1 year, 3 years, 5 years, and 10 years; a total of 7 events). During this task, participants will also generate corresponding short text descriptions that will be used as cues to prompt episodic thinking in the natural environment. Participants will regenerate all cues during weeks 8, 16, and 24, with partial regenerations (regenerating only the 1 month and 3 month cues) scheduled during weeks 12 and 20. Participants will complete delay discounting tasks while viewing and imagining their EFT or HIT cues in weeks 3 and 16.

On the day following the event/cue generation, participants will begin thrice-daily smartphone app prompts to engage in EFT. In each prompt, participants will be presented with one of their EFT cues, chosen randomly, and asked to read and vividly imagine this event for a period of 30-60 seconds in a quiet location.

In contrast to the EFT condition, the control condition will be healthy information thinking (HIT). Specifically, participants assigned to the HIT group will be asked to read informational health vignettes on various topics related to T2D and health, adapted from publicly available information (e.g., information on the role of insulin and insulin resistance in T2D, nutrition labeling, understanding T2D risk factors). Participants will then be asked to describe, in 1-2 sentences, a specific piece of information they learned about each topic. This process is designed to mimic the event generation task used for the EFT group, with the number of topics matched to the number of future EFT events. Beginning in Week 3, participants will receive smartphone prompts to read and consider their self-generated topic descriptions with the same frequency and at approximately the same times of day as the EFT group. Moreover, HIT participants will regenerate these descriptions with the same frequency as the EFT group.

At Weeks 8 and 24, participants will complete the same primary and secondary outcome measures they completed during the baseline week, including delay discounting, BMI, and HbA1c.

In addition, during a debriefing stage after Week 24, participants will also rate the perceived helpfulness and convenience of each intervention component (EFT/control prompting, diet and activity support, self-monitoring, and case management) and remote outcomes assessment methods.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • HbA1c greater than or equal to 7.7%
  • from urban or rural area
  • body mass index greater than or equal to 30

Exclusion criteria

  • gestational diabetes
  • pregnancy or lactating
  • not ambulatory
  • intellectual impairment
  • unmanaged comorbid psychiatric diagnosis (including eating disorders)

Treatment and study plan

Episodic Future Thinking

Behavioral

Participants will be prompted three times daily to think vividly about personally meaningful future events.

Healthy Information Thinking

Behavioral

Participants will be prompted three times daily to think about their responses to informational health vignettes.

Primary outcomes

  1. Change in glycemic control from baseline (Week 0) to Week 8

    Time frame: Baseline, Week 8

    Hemoglobin A1c (HbA1C) will be assessed by the A1CNOW system

  2. Change in glycemic control from baseline (Week 0) to Week 24

    Time frame: Baseline, Week 24

    Hemoglobin A1c (HbA1C) will be assessed by the A1CNOW system

  3. Change in body mass index from baseline (Week 0) to Week 8

    Time frame: Baseline, Week 8

    Weight will be assessed with a wireless-enabled scale. Height will be assessed through self-report. Height and weight will be used to calculate BMI (kg/m2).

  4. Change in body mass index from baseline (Week 0) to Week 24

    Time frame: Baseline, Week 24

    Weight will be assessed with a wireless-enabled scale. Height will be assessed through self-report. Height and weight will be used to calculate BMI (kg/m2).

Secondary outcomes

  1. Change in dietary intake from baseline (Week 0) to Week 8

    Time frame: Baseline, Week 8

    Dietary intake will be assessed by ASA-24 online food recalls

  2. Change in dietary intake from baseline (Week 0) to Week 24

    Time frame: Baseline, Week 24

    Dietary intake will be assessed by ASA-24 online food recalls

  3. Change in physical activity from baseline (Week 0) to Week 8

    Time frame: Baseline, Week 8

    Physical activity will be assessed using the International Physical Activity Questionnaire Short Form (IPAQ-SF)

  4. Change in physical activity from baseline (Week 0) to Week 24

    Time frame: Baseline, Week 24

    Physical activity will be assessed using the International Physical Activity Questionnaire Short Form (IPAQ-SF)

  5. Change in self-reported adherence to glucose-lowering medication from baseline (Week 0) to Week 8

    Time frame: Baseline, Week 8

    Medication adherence will self reported by an 11-point assessment. Participants will self-report the frequency they have taken all of their glucose-lowering medications

  6. Change in self-reported adherence to glucose-lowering medication from baseline (Week 0) to Week 24

    Time frame: Baseline, Week 24

    Medication adherence will self reported by an 11-point assessment. Participants will self-report the frequency they have taken all of their glucose-lowering medications

  7. Ease of Use and Treatment Effectiveness Questionnaire, Likert scale

    Time frame: Week 24

    Perceived ease of use and effectiveness of assessment methods and intervention components will be collected by self-reported ratings on 5-point Likert-style scales.

Other outcomes

  1. Change in delay discounting from baseline (Week 0) to Week 8

    Time frame: Baseline, Week 8

    Monetary delay discounting will be assessed by an adjusting-amount task

  2. Change in delay discounting from baseline (Week 0) to Week 24

    Time frame: Baseline, Week 24

    Monetary delay discounting will be assessed by an adjusting-amount task

Sponsors and collaborators

Lead sponsor

Virginia Polytechnic Institute and State University

Other

Collaborators

  • Carilion Clinic
  • University at Buffalo

Registry information

Official study title

Episodic Future Thinking to Improve Management of Type 2 Diabetes in Rural and Urban Patients: Remote Delivery and Outcomes Assessment to Increase Reach and Dissemination

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Mar 15, 2022
Registry last updated
Jun 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.